聚焦于高密度脂蛋白以降低冠心病风险。

Focusing on high-density lipoprotein for coronary heart disease risk reduction.

机构信息

Department of Medicine, Section of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA.

出版信息

Cardiol Clin. 2011 Feb;29(1):105-22. doi: 10.1016/j.ccl.2010.11.005.

DOI:10.1016/j.ccl.2010.11.005

PMID:21257103

Abstract

A low level of high-density lipoprotein (HDL) is an acknowledged risk factor for coronary heart disease (CHD). HDL cholesterol (HDL-C) exerts its primary cardioprotective effect through a reverse cholesterol transport process, and suppression of this process has been the focus of the development of novel therapeutic agents for increasing HDL-C levels. Several strategies can be used to increase HDL-C levels to target cardiovascular risk reduction. This article presents a review of the biologic actions of HDL that can serve as a potential basis for antiatherosclerotic activity and discusses strategies for targeting HDL for CHD risk reduction.

摘要

高密度脂蛋白（HDL）水平低是冠心病（CHD）的公认危险因素。HDL 胆固醇（HDL-C）通过胆固醇逆转运过程发挥其主要的心脏保护作用，抑制这一过程一直是开发新型升高 HDL-C 水平治疗药物的重点。有几种策略可用于升高 HDL-C 水平以降低心血管风险。本文综述了 HDL 的生物学作用，这些作用可能为抗动脉粥样硬化活性提供潜在基础，并讨论了针对 CHD 降低风险的 HDL 靶向策略。